{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:56:51Z","timestamp":1790776611537,"version":"4.1.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MRC_MC_UU_00002\/11"],"award-info":[{"award-number":["MRC_MC_UU_00002\/11"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Trastuzumab is a valuable therapy option for women with ERBB2(HER2)+ breast cancer tumours, often used in combination with chemotherapy and alongside other therapies. It is known to have adverse effects, but these have proved difficult to separate from the effects of other concurrent therapies patients are usually taking. This study aims to assess the adverse effects specifically attributable to trastuzumab, and whether they vary by patient subgroup or concurrent therapies.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>As registered on PROSPERO (CRD42019146541), we used previous systematic reviews as well as the clinicaltrials.gov registry to identify randomised controlled trials in breast cancer which compared treatment regimes with and without trastuzumab. Neoadjuvant, adjuvant and metastatic settings were examined. Data was extracted from those which had, as of July 2022, reported adverse events. Risk of bias was assessed using ROB2. Primary outcomes were adverse events of any type or severity (excluding death). A standard random-effects meta-analysis was performed for each outcome independently. In order to ascertain whether adverse effects differed by individual factors such as age or tumour characteristics, or by use of trastuzumab concurrently with hormone therapy, we examined individual-level patient data for one large trial, HERA.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>79 relevant trials were found, of which 20 contained comparable arms of trastuzumab-containing therapy and corresponding matched therapy without trastuzumab. This allowed a comparison of 8669 patients receiving trastuzumab versus 9556 receiving no trastuzumab, which gave a list of 25 statistically and clinically significant adverse effects related to trastuzumab alone: unspecified pain, asthenia, nasopharyngitis, skin disorders (mainly rash), dyspepsia, paraesthesia, infections (often respiratory), increased lacrimation, diarrhoea, myalgia, oedema (limb\/peripheral), fever, nose bleeds, cardiac events, insomnia, cough, back pain, dyspnoea, chills, dizziness or vertigo, hypertension, congestive heart failure, increased levels of aspartate aminotransferase, gastrointestinal issues and dehydration. Analysis of individual patient-level data from 5102 patients suggested that nausea is slightly more likely for women taking trastuzumab who are ER+ \/also taking hormone therapy than for those who are ER-\/not taking hormone therapy; no other potential treatment-subgroup interactions were detected. We found no evidence for significantly increased rates of neutropenia, anaemia or lymphopenia in patients on trastuzumab-containing regimes compared to those on comparable regimes without trastuzumab.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This meta-analysis should allow clinicians and patients to better identify and quantify the potential adverse effects of adding trastuzumab to their treatment regime for breast cancer, and hence inform their decision-making. However, limitations include serious risk of bias due to heterogeneity in reporting of the outcomes and the open-label nature of the trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0275321","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T20:09:32Z","timestamp":1669925372000},"page":"e0275321","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"given":"Christopher","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0414-3207","authenticated-orcid":true,"given":"Leila","family":"Finikarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-161X","authenticated-orcid":true,"given":"Alexandra L. J.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"pone.0275321.ref001","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II Study of Weekly Intravenous Recombinant Metastatic Breast Cancer","volume":"14","author":"BJ Baselga","year":"1996","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref002","article-title":"Trastuzumab containing regimens for early breast cancer (Review) Summary of findings for main comparison","author":"L Moja","year":"2012","journal-title":"Cochrane Database ofSystematic Rev"},{"key":"pone.0275321.ref003","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.3390\/cancers13143540","article-title":"Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma","volume":"13","author":"H Maadi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"pone.0275321.ref004","unstructured":"Food and drugs administration (2010) HERCEPTIN\u00ae (Trastuzumab) Final labelling evidence."},{"key":"pone.0275321.ref005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2 -Mutant Non\u2013Small-Cell Lung Cancer","volume":"386","author":"BT Li","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0275321.ref006","article-title":"Trastuzumab deruxtecan: Changing the destiny of her2 expressing solid tumors","author":"A Indini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"pone.0275321.ref007","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.cco.0000228734.32261.62","article-title":"Adverse effects of the humanized antibodies used as cancer therapeutics","volume":"18","author":"J Klastersky","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"pone.0275321.ref008","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/15569527.2020.1833028","article-title":"Dermatological side effects of targeted antineoplastic therapies: a prospective study","volume":"39","author":"S Agirgol","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"key":"pone.0275321.ref009","author":"Roche","year":"2021","journal-title":"Herceptin: Summary of Product Characteristics"},{"key":"pone.0275321.ref010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajco.12206","article-title":"Systemic treatment of HER2-positive metastatic breast cancer: A systematic review","volume":"10","author":"N Wilcken","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"pone.0275321.ref011","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical experience","volume":"20","author":"A Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref012","first-page":"CD006242","article-title":"Trastuzumab-containing regimens for metastatic breast cancer","volume":"6","author":"S Balduzzi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0275321.ref013","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11523-015-0409-2","article-title":"Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group","volume":"11","author":"SC Sodergren","year":"2016","journal-title":"Target Oncol"},{"key":"pone.0275321.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.f5577","article-title":"Comparative effectiveness of exercise and drug interventions on mortality outcomes: Metaepidemiological study","volume":"347","author":"H Naci","year":"2013","journal-title":"BMJ"},{"key":"pone.0275321.ref015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/bjsports-2018-099921","article-title":"How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure","volume":"53","author":"H Naci","year":"2019","journal-title":"Br J Sports Med"},{"key":"pone.0275321.ref016","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial","volume":"382","author":"A Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"pone.0275321.ref017","first-page":"2159","article-title":"Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG. J Clin Oncol","volume":"32","author":"Procter MJ Azambuja E De","year":"2014"},{"key":"pone.0275321.ref018","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(11)70033-X","article-title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","volume":"12","author":"L Gianni","year":"2011","journal-title":"Lancet Oncol"},{"key":"pone.0275321.ref019","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1200\/JCO.2009.23.0946","article-title":"Trastuzumab for Patients With Axillary-Node\u2013Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial","volume":"27","author":"M Spielmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel","volume":"375","author":"L Gianni","journal-title":"Lancet"},{"key":"pone.0275321.ref021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.breast.2011.07.006","article-title":"Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer\u2014Results of the eLEcTRA trial","volume":"21","author":"J Huober","year":"2012","journal-title":"Breast"},{"key":"pone.0275321.ref022","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-006-9306-9","article-title":"Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer","volume":"101","author":"G Gasparini","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0275321.ref023","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"DJ Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"pone.0275321.ref024","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"AU Buzdar","year":"2005","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref025","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1002\/cncr.25309","article-title":"Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment","volume":"116","author":"HR Chang","year":"2010","journal-title":"Cancer"},{"key":"pone.0275321.ref026","article-title":"NCT00068341 clinical trials registry results: Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer","author":"Jonsson Comprehensive Cancer Center","year":"2017","journal-title":"ClinicalTrials.gov"},{"key":"pone.0275321.ref027","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leu","volume":"26","author":"AD Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref028","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/annonc\/mdt508","article-title":"Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: Final results of a randomized phase III study (ABCSG-24)","volume":"25","author":"GG Steger","year":"2014","journal-title":"Ann Oncol"},{"key":"pone.0275321.ref029","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"D Cameron","year":"2017","journal-title":"Lancet"},{"key":"pone.0275321.ref030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-010-0939-3","article-title":"A multicenter randomized phase II study of sequential epirubicin \/ cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients","volume":"122","author":"J-Y Pierga","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0275321.ref031","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study","volume":"27","author":"B Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref032","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group","volume":"23","author":"M Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref033","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","article-title":"Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial","volume":"13","author":"M Untch","year":"2012","journal-title":"Lancet"},{"key":"pone.0275321.ref034","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer","volume":"354","author":"R Kokko","year":"2006","journal-title":"N Engl J Med"},{"key":"pone.0275321.ref035","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.ejca.2011.06.021","article-title":"Trastuzumab beyond progression: Overall survival analysis of the GBG 26\/BIG 3\u201305 phase III study in HER2-positive breast cancer","volume":"47","author":"G Von Minckwitz","year":"2011","journal-title":"Eur J Cancer"},{"key":"pone.0275321.ref036","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26\/Breast International Group 03\u201305 study","volume":"27","author":"G Von Minckwitz","year":"2009","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref037","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/jco.2008.26.15_suppl.1025","article-title":"Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26\/BIG 3\u201305)","volume":"26","author":"G Von Minckwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref038","article-title":"NCT01275677 clinical trial registry results: Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","author":"National Cancer Institute (NCI)","year":"2020","journal-title":"In: ClinicalTrials.gov"},{"key":"pone.0275321.ref039","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+","volume":"38","author":"L Fehrenbacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref040","article-title":"NCT00045032 Clinical registry results: Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer (HERA)","author":"Hoffmann-La Roche","year":"2017","journal-title":"In: ClinicalTrials.gov"},{"key":"pone.0275321.ref041","article-title":"NCT00022672 clinical trial registry results: A Study to Evaluate the Efficacy and Safety of Herceptin\u00ae (Trastuzumab) in Combination With Arimidex\u00ae (Anastrozole) an Aromatase Inhibitor Compared to Arimidex\u00ae Alone in Patients With Metastatic Breast Cancer","author":"Hoffmann-La Roche","year":"2013","journal-title":"In: ClinicalTrials.gov"},{"key":"pone.0275321.ref042","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-013-2755-z","article-title":"Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43","volume":"142","author":"KP Siziopikou","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0275321.ref043","article-title":"NCT00769379 clinical trial registry results: Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","author":"National Cancer Institute (NCI)","year":"2022","journal-title":"In: ClinicalTrials.gov"},{"key":"pone.0275321.ref044","article-title":"NCT00971737 clinical trial registry results: Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer","author":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","year":"2019","journal-title":"In: ClinicalTrials.gov"},{"key":"pone.0275321.ref045","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2 \u2013Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31","volume":"29","author":"EA Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref046","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer","volume":"353","author":"EH Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0275321.ref047","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1200\/JCO.2011.36.7045","article-title":"Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer","volume":"29","author":"EA Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref048","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial","volume":"34","author":"PP Advani","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref049","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","volume":"365","author":"D Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0275321.ref050","article-title":"NCT00021255 clinical trials registry results: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","author":"Sanofi","year":"2016","journal-title":"In: ClinicalTrials.gov"},{"key":"pone.0275321.ref051","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ctrv.2013.09.002","article-title":"A systematic review of dual targeting in HER2-positive breast cancer","volume":"40","author":"I K\u00fcmler","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"pone.0275321.ref052","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/OTT.S183304","article-title":"Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: A systematic review and meta-analysis","volume":"12","author":"W Ma","year":"2019","journal-title":"Onco Targets Ther"},{"key":"pone.0275321.ref053","article-title":"Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis","author":"D Wu","year":"2019","journal-title":"J Oncol"},{"key":"pone.0275321.ref054","first-page":"1","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"key":"pone.0275321.ref055","first-page":"26","article-title":"meta: An R Package for Meta-Analysis","volume":"7","author":"G Schwarzer","year":"2007","journal-title":"R News"},{"key":"pone.0275321.ref056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0246441","article-title":"The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis","volume":"16","author":"C Jackson","year":"2021","journal-title":"PLoS One"},{"key":"pone.0275321.ref057","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer","volume":"20","author":"CL Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"pone.0275321.ref058","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-014-3184-3","article-title":"Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis","volume":"149","author":"T Funakoshi","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0275321.ref059","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10549-007-9548-1","article-title":"Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy","volume":"107","author":"D Cella","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0275321.ref060","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.breast.2005.08.012","article-title":"Acceptance of adjuvant therapy and quality of life issues","volume":"14","author":"L Fallowfield","year":"2005","journal-title":"Breast"},{"key":"pone.0275321.ref061","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ejca.2006.03.004","article-title":"Intentional and non-intentional non-adherence to medication amongst breast cancer patients","volume":"42","author":"L Atkins","year":"2006","journal-title":"Eur J Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T20:10:10Z","timestamp":1669925410000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0275321"}},"subtitle":[],"editor":[{"given":"Alessandro","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0275321","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}